Guideline for overactive bladder adds new treatments

Updated recommendations for the diagnosis and treatment of non-neurogenic overactive bladder incorporate two new treatments approved since 2012 – oral mirabegron and intradetrusor injection of...

Field of Interest: Pulmonology
Type: News Item

Benefits outweigh harms of aspirin therapy

Prophylactic aspirin therapy of at least 5 years’ duration has a favorable benefit-harm profile, primarily because of its effectiveness in preventing colorectal and other cancers, according to a...

Field of Interest: Gastroentero...
Type: News Item

Benefits outweigh harms of aspirin therapy

Prophylactic aspirin therapy of at least 5 years’ duration has a favorable benefit-harm profile, primarily because of its effectiveness in preventing colorectal and other cancers, according to a...

Field of Interest: Oncology
Type: News Item

Bisphosphonates don’t cut risk of breast cancer

Three to four years of therapy with the bisphosphonates alendronate and zoledronic acid, taken at doses used to treat osteoporosis, did not decrease the risk of incident breast cancer in...

Field of Interest: Oncology
Type: News Item

Bisphosphonates don’t cut risk of breast cancer

Three to four years of therapy with the bisphosphonates alendronate and zoledronic acid, taken at doses used to treat osteoporosis, did not decrease the risk of incident breast cancer in...

Field of Interest: Pulmonology
Type: News Item

Mobile teledermatology predicted to be a game changer

COEUR D’ALENE, IDAHO – Teledermatology is gathering steam – and supportive data – as a potentially invaluable way to address the overlapping problems of a dermatology workforce shortage, gruelingly...

Field of Interest: Dermatology
Type: News Item

One in six SLE patients readmitted in 30 days

One in six patients with systemic lupus erythematosus was readmitted within 30 days after discharge in a multistate, administrative database study of more than 800 hospitals and 55,000...

Field of Interest: Rheumatology
Type: News Item

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness